g) As per revised protocol 02 this criteria is now combined with criteria f). h) Participants who experienced prior Grade 1 to 2 immunotherapy therapy-related immune- mediated AEs must have confirmed recovery from these events at the time of study entry, other than endocrinopathies treated with supplementation, as documented by resolution of all r elated clin ical symptoms , abnormal findings on physical examination, and/or associated laboratory abnormali ties. Where applicable, these participants must also have completed steroid tapers for treatment of these AEs by a minimum of 14 days prior to commencing treatment with study treatment. i) Eligibility of participants with prior Grade ≥3 checkpoint therapy-related immune AEs will be considered on a case-by-case basi s after discussion with the BMS Medical Monitor/Study Director (or designee) (eg, asymptomatic isolated Grade 3 lipase elevations without clinical or radiological features of pancreatitis will be permitted to enroll). j)“Not applicable as per revised protocol 02” In an effort to limi t confounding factors, for all cohorts where applicable, no more than 5 par ticipants previously found to be “rapid progressors” ( time to tr eatment failure ≤2 months) on anti-PD-1, anti-PD-L1, or anti- CTLA-4 therapy should be enrolled per cohort. k) ECOG performance status ≤2 l) Prior palliative radiotherapy must have been completed at least 2 weeks prior to the first dose of the study treatment. Participants with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of the first dose of study treatment are strongly encouraged to receive palliative radiotherapy prior to enrollment. 3) The following tumor types will be explored: a) CRC i) Participants must have histologically confirmed CRC that is metastatic or recurrent with documented disease progression. ii) Document microsatellite instability (MSI), mismatch repair (MMR), KRAS, and BRAF status if known. iii) Prior therapy requir ement: Participants must have received at least 1, but no more than 3, prior systemic therapies for metastatic and/or unresectable disease (or have progressed within 6 months of adjuvant therapy). iv) Participant must have incurable metastatic disease (ie, participants with disease that is potentially curable by surgical re section are not eligible for treatment). v) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease Revised Protocol No.: 04 Date: 31-May-2019 71 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS stage and condition, in the country where they are receiving treatment, if such a regimen exists. Reason(s) for refusal should be documented. b) HNSCC (oral cavity, pharynx, larynx) i) Participants must have histologically confi rmed incurable, locally advanced, recurrent, or metastatic HNSCC (oral cavity, pharynx, larynx), Stage III or IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy). ii) Participants should have documented HPV stat us (can be inferred by p16 staining) and, if known, subtype (HPV16/18). iii)“Not applicable as per revised protocol 03” Participants must have received and then progressed or have been intolerant or refractory to at least 1 but no more than 2 prior systemic therapies (eg, platinum-based chemotherapy) regimen for the treatment of metastatic or locally advanced unresectable disease. iv) Prior curative radiation therapy must have been completed at least 4 weeks prior to study treatment administration. Prior focal palliative radiotherapy must have been completed at least 2 weeks before study treatment administration. v) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving tr eatment, if such a regimen exists. Reason(s) for refusal should be documented. vi) Participants must have received and then progressed or have been intolerant or refractory to at least 1 but no more than 3 prior systemic therapies (eg, platinum-based chemotherapy) regimen for th e treatment of metastatic or lo cally advanced unresectable disease c) NSCLC i) Participants must have histologic or cytologic confirmation of NSCLC (per the seventh International Association for the Study of Lung Cancer [IASLC]) with squamous or nonsquamous histology that is advanced (metastatic and/or unresectable). ii) “Not applicable as per revised protocol 03” Participants must have had at least 1, but not more than 2, prior systemic therapies for NSCLC. Maintenance, adjuvant, or neoadjuvant (chemotherapy or chemoradiation) therapy do not count as an additional line of treatment. iii) Participants s hould have been offered a platinum-based chemotherapy for NSCLC. The platinum-based chemotherapy may have been in the adjuvant, neoadjuvant, or chemoradiation setting. Participants with recurrent/metastatic disease that has recurred within 6 months of completing such treatment are consid ered eligible for st udy treatment. Prior adjuvant or neoadjuvant chemot herapy is permitted as long as the last administration of the prior regimen occurred at least 4 weeks prior to enrollment. iv) Prior definitive chemoradiation for locally advanced disease is also permitted as long as the last administration of chemotherapy or radiotherapy (whichever was given last) occurred at least 4 weeks prior to enrollment. v) Participants with known EGFR mutations or ALK rearrangements must have received EGFR or ALK inhibitors, respectively. EGFR, ALK, KRAS, and ROS1 mutational status must be documented, if known. Revised Protocol No.: 04 Date: 31-May-2019 72 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS vi) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving tr eatment, if such a regimen exists. Reason(s) for refusal should be documented.